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or patients with decompensated biventricular heart failure
refractory to medical management, the total artificial heart
(TAH) is a sufficient therapy option. One possible postop-
erative problem is the compression of the superior vena
cava (SVC) caused by bleeding that will lead to tamponade with
low output of the TAH.
In a 55-year-old man, such a TAH was implanted as a bridge to
transplantation without any perioperative complications. However,
7 months after the patient was discharged home, he was readmitted
with signs of congestion of the upper body and low flow of the TAH
because of SVC compression caused by pericardial effusion. In an
interventional procedure a stent was implanted in the SVC, which
led to full recovery of the patient and normal flow patterns of the
TAH.
Clinical Summary
We implanted a TAH (CardioWest temporary Total Artificial Heart
System; SynCardia Systems, Inc, Tucson, Ariz) in a 55-year-old
manwith decompensated biventricular heart failure caused by ische-
mic cardiomyopathy. The initial evaluation showed that he was not
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doi:10.1016/j.jtcvs.2007.10.014The Journal of Thoa candidate for high-urgency transplantation or for only left ventric-
ular assist device implantation because of very bad right ventricular
function (right ventricular stroke work index,,300 mm Hg3 mL/
m2/beat; central venous pressure, .20 mm Hg).
After an initial uneventful course, hewas discharged home.Seven
months later, the patient was readmitted to our center because of
upper body congestion and decreasing flow of the TAH. Computed
tomographic (CT) scanning demonstrated a nearly complete com-
pression of the SVC with only minimal rest flow to the right atrium
because of pericardial effusion (Figure 1,A) as a result of a tiny bleed
of the anastomosis between the outflow cannula and the ascending
aorta. In the actual CT scan with contrast medium, no bleeding could
be detected, and therefore we abandoned reoperation to avoid the
consecutive risks after this long-term TAH implantation.
In cooperation with the department of radiology, we implanted
interventionally a stent in the compressed SVC. The initial angio-
graphic analysis demonstrated the compression of the SVC, with
onlyminimal rest flow to the right atrium (Figure 1,B). Then a guide-
wire was carefully inserted under radioscopic control to avoid
blockade of the mechanical valve of the TAH; subsequently,
a Wall stent (Boston Scientific Corporation, Natick, Mass) with
a 16-mm diameter and a 6-cm length was placed in the SVC. The
postinterventional angiographic control showed normal flow over
the stented SVC (Figure 2, A). Immediately after the procedure,
the flow of the TAH recovered to normal values, and the congestion
of the upper body decreased within a few days, so that the patient
could be discharged home again only 3 days later. A control CT
scan 8 weeks later showed a wide-open stent in the SVC (Figure 2,
B) while the patient was still symptom free, and the TAH showed
normal flow patterns. The pericardial effusion was constant, and
no active bleeding was seen.
Discussion
Resulting from the shortage of organ donors with increasing num-
bers of patients with congestive heart failure, the development of
ventricular assist devices has been required and is today an acceptedFigure 1. A, Reconstructed computed
tomographic scan of the thorax. The
arrow indicates the nearly completely
interrupted superior vena cava by mas-
sive pericardial effusion. Active bleed-
ing is excluded. B, Preinterventional
angiography shows a nearly completely
restricted superior vena cava. TAH,
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Brief CommunicationsFigure 2. A, Postinterventional angiog-
raphy of the superior vena cava (V.cava.
sup)with expanded stent and normal in-
flow into the right atrium. B, Recon-
structed computed tomographic scan
of the thorax 8 weeks after intervention
demonstrated the open stent. V.cava.
sup, Superior vena cava.therapy option in many of these patients. However, there is still
a subgroup that is not eligible for this therapy option, especially
patients with decompensated biventricular heart failure that is re-
fractory to medical management with consecutive beginning sec-
ondary organ failure. For this subgroup, the TAH is a sufficient
therapy option1,2 if they fulfill the selection criteria.3 Among the
possible complications1-4 is bleeding in the early course after im-
plantation. This can lead to compression of the SVC with consecu-
tive signs of tamponade and low output of the TAH. In this case the
only therapy option is immediate reoperation to exculpate the
pericardium from the effusion and to detect the bleeding source.
In patients with a long-term TAH, the interventional therapy of
compression of the SVC because of pericardial effusion is, in our
opinion, possible if no actual bleeding source can be detected.
Most important for this interventional procedure is to avoid the
blockade of the valve of the artificial right ventricle with the456 The Journal of Thoracic and Cardiovascular Surgery c Febguidewire. The advantages are obvious: there is no need to change
the anticoagulation therapy, a reoperation procedure with all its peri-
operative risks can be avoided, and the patient can be discharged
home rapidly.
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